You're asking about **1-[5-hydroxy-3-methyl-5-(3-pyridinyl)-4H-pyrazol-1-yl]-2-(4-methylphenyl)ethanone**. This is a rather complex chemical name, and understanding its significance requires some background in chemistry and pharmacology.
**Here's what we can break down:**
* **Structure:** This chemical name describes a specific molecule. The long string of characters tells us the arrangement of atoms and bonds within the molecule. It belongs to a family of compounds called **pyrazoles**, which are five-membered ring structures containing nitrogen.
* **Functional Groups:** This compound contains several functional groups, such as a hydroxyl (-OH), a methyl (-CH3), and a pyridinyl group (a six-membered ring containing nitrogen). These groups contribute to the compound's chemical properties and potential biological activity.
* **Potential Biological Activity:** The presence of these specific functional groups suggests that this compound could interact with biological systems, potentially acting as a **drug** or a **probe** for biological research.
**Why it's important for research:**
* **Drug Development:** Scientists often synthesize and study new compounds like this to identify potential drug candidates for various diseases. By understanding the compound's interactions with biological targets, researchers can design better and more effective therapies.
* **Biological Research:** The compound could be a valuable tool for understanding the mechanisms of disease. For example, it could be used to study the activity of specific enzymes or receptors involved in disease processes.
* **Synthesis and Chemistry:** Studying the synthesis and properties of this compound can contribute to the development of new synthetic methods and understanding of the chemistry of pyrazoles.
**To determine its exact importance, we need more context.** For example:
* **What is its target?** Does it interact with a specific enzyme, receptor, or other biological target?
* **What are its biological effects?** Does it have any therapeutic potential?
* **What research is being done with it?** Are there any published studies on this compound?
**To find more information, you could:**
* **Search scientific databases:** PubChem, ChemSpider, and SciFinder are good places to start.
* **Consult research articles:** Look for articles that mention the compound by name or structure.
* **Contact experts in the field:** Researchers specializing in drug discovery or pyrazole chemistry could provide more insights.
I hope this explanation helps!
ID Source | ID |
---|---|
PubMed CID | 3123702 |
CHEMBL ID | 1460795 |
CHEBI ID | 105708 |
Synonym |
---|
OPREA1_757845 |
3-methyl-1-[(4-methylphenyl)acetyl]-5-(3-pyridinyl)-4,5-dihydro-1h-pyrazol-5-ol |
AG-205/37159041 |
OPREA1_453966 |
smr000163361 |
MLS000545200 , |
CHEBI:105708 |
AKOS000602299 |
1-(5-hydroxy-3-methyl-5-pyridin-3-yl-4h-pyrazol-1-yl)-2-(4-methylphenyl)ethanone |
1-[5-hydroxy-3-methyl-5-(pyridin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl]-2-(4-methylphenyl)ethanone |
STK760380 |
HMS2354G11 |
AKOS022016479 |
CHEMBL1460795 |
1-[5-hydroxy-3-methyl-5-(3-pyridinyl)-4h-pyrazol-1-yl]-2-(4-methylphenyl)ethanone |
Q27183466 |
1-[5-hydroxy-3-methyl-5-(pyridin-3-yl)-4,5-dihydro-1h-pyrazol-1-yl]-2-(4-methylphenyl)ethan-1-one |
Class | Description |
---|---|
acetamides | Compounds with the general formula RNHC(=O)CH3. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 31.6228 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 3.5481 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 10.0000 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 23.7781 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 112.2020 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 22.1969 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 3.9811 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 3.9811 | 1.0000 | 10.4756 | 28.1838 | AID901 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |